A Global Survey on the Impact of COVID-19 on Urological Services.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 20 04 2020
accepted: 19 05 2020
pubmed: 9 6 2020
medline: 15 8 2020
entrez: 9 6 2020
Statut: ppublish

Résumé

The World Health Organization (WHO) declared coronavirus disease-19 (COVID-19) as a pandemic on March 11, 2020. The impact of COVID-19 on urological services in different geographical areas is unknown. To investigate the global impact of COVID-19 on urological providers and the provision of urological patient care. A cross-sectional, web-based survey was conducted from March 30, 2020 to April 7, 2020. A 55-item questionnaire was developed to investigate the impact of COVID-19 on various aspects of urological services. Target respondents were practising urologists, urology trainees, and urology nurses/advanced practice providers. The primary outcome was the degree of reduction in urological services, which was further stratified by the geographical location, degree of outbreak, and nature and urgency of urological conditions. The secondary outcome was the duration of delay in urological services. A total of 1004 participants responded to our survey, and they were mostly based in Asia, Europe, North America, and South America. Worldwide, 41% of the respondents reported that their hospital staff members had been diagnosed with COVID-19 infection, 27% reported personnel shortage, and 26% had to be deployed to take care of COVID-19 patients. Globally, only 33% of the respondents felt that they were given adequate personal protective equipment, and many providers expressed fear of going to work (47%). It was of concerning that 13% of the respondents were advised not to wear a surgical face mask for the fear of scaring their patients, and 21% of the respondents were advised not to discuss COVID-19 issues or concerns on media. COVID-19 had a global impact on the cut-down of urological services, including outpatient clinic appointments, outpatient investigations and procedures, and urological surgeries. The degree of cut-down of urological services increased with the degree of COVID-19 outbreak. On average, 28% of outpatient clinics, 30% of outpatient investigations and procedures, and 31% of urological surgeries had a delay of >8 wk. Urological services for benign conditions were more affected than those for malignant conditions. Finally, 47% of the respondents believed that the accumulated workload could be dealt with in a timely manner after the COVID-19 outbreak, but 50% thought the postponement of urological services would affect the treatment and survival outcomes of their patients. One of the limitations of this study is that Africa, Australia, and New Zealand were under-represented. COVID-19 had a profound global impact on urological care and urology providers. The degree of cut-down of urological services increased with the degree of COVID-19 outbreak and was greater for benign than for malignant conditions. One-fourth of urological providers were deployed to assist with COVID-19 care. Many providers reported insufficient personal protective equipment and support from hospital administration. Coronavirus disease-19 (COVID-19) has led to significant delay in outpatient care and surgery in urology, particularly in regions with the most COVID-19 cases. A considerable proportion of urology health care professionals have been deployed to assist in COVID-19 care, despite the perception of insufficient training and protective equipment.

Sections du résumé

BACKGROUND BACKGROUND
The World Health Organization (WHO) declared coronavirus disease-19 (COVID-19) as a pandemic on March 11, 2020. The impact of COVID-19 on urological services in different geographical areas is unknown.
OBJECTIVE OBJECTIVE
To investigate the global impact of COVID-19 on urological providers and the provision of urological patient care.
DESIGN, SETTING, AND PARTICIPANTS METHODS
A cross-sectional, web-based survey was conducted from March 30, 2020 to April 7, 2020. A 55-item questionnaire was developed to investigate the impact of COVID-19 on various aspects of urological services. Target respondents were practising urologists, urology trainees, and urology nurses/advanced practice providers.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS METHODS
The primary outcome was the degree of reduction in urological services, which was further stratified by the geographical location, degree of outbreak, and nature and urgency of urological conditions. The secondary outcome was the duration of delay in urological services.
RESULTS AND LIMITATIONS CONCLUSIONS
A total of 1004 participants responded to our survey, and they were mostly based in Asia, Europe, North America, and South America. Worldwide, 41% of the respondents reported that their hospital staff members had been diagnosed with COVID-19 infection, 27% reported personnel shortage, and 26% had to be deployed to take care of COVID-19 patients. Globally, only 33% of the respondents felt that they were given adequate personal protective equipment, and many providers expressed fear of going to work (47%). It was of concerning that 13% of the respondents were advised not to wear a surgical face mask for the fear of scaring their patients, and 21% of the respondents were advised not to discuss COVID-19 issues or concerns on media. COVID-19 had a global impact on the cut-down of urological services, including outpatient clinic appointments, outpatient investigations and procedures, and urological surgeries. The degree of cut-down of urological services increased with the degree of COVID-19 outbreak. On average, 28% of outpatient clinics, 30% of outpatient investigations and procedures, and 31% of urological surgeries had a delay of >8 wk. Urological services for benign conditions were more affected than those for malignant conditions. Finally, 47% of the respondents believed that the accumulated workload could be dealt with in a timely manner after the COVID-19 outbreak, but 50% thought the postponement of urological services would affect the treatment and survival outcomes of their patients. One of the limitations of this study is that Africa, Australia, and New Zealand were under-represented.
CONCLUSIONS CONCLUSIONS
COVID-19 had a profound global impact on urological care and urology providers. The degree of cut-down of urological services increased with the degree of COVID-19 outbreak and was greater for benign than for malignant conditions. One-fourth of urological providers were deployed to assist with COVID-19 care. Many providers reported insufficient personal protective equipment and support from hospital administration.
PATIENT SUMMARY RESULTS
Coronavirus disease-19 (COVID-19) has led to significant delay in outpatient care and surgery in urology, particularly in regions with the most COVID-19 cases. A considerable proportion of urology health care professionals have been deployed to assist in COVID-19 care, despite the perception of insufficient training and protective equipment.

Identifiants

pubmed: 32507625
pii: S0302-2838(20)30371-7
doi: 10.1016/j.eururo.2020.05.025
pmc: PMC7248000
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

265-275

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Références

J Am Acad Orthop Surg. 2020 Jun 1;28(11):e456-e464
pubmed: 32282439
BJU Int. 2020 Jun;125(6):E15-E17
pubmed: 32274879
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
JAMA. 2020 Jun 2;323(21):2133-2134
pubmed: 32259193
Urol J. 2020 May 16;17(3):326
pubmed: 32207540
JAMA Netw Open. 2020 Mar 2;3(3):e203976
pubmed: 32202646
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Minerva Urol Nefrol. 2020 Aug;72(4):505-509
pubmed: 32253371
Eur Urol. 2020 Jul;78(1):e38-e39
pubmed: 32192816
J Travel Med. 2020 Mar 13;27(2):
pubmed: 31943059
Asian J Urol. 2020 Apr;7(2):149-160
pubmed: 32257808
EClinicalMedicine. 2020 Apr 05;21:100331
pubmed: 32292899

Auteurs

Jeremy Yuen-Chun Teoh (JY)

S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China. Electronic address: jeremyteoh@surgery.cuhk.edu.hk.

William Lay Keat Ong (WLK)

Department of Urology, Penang General Hospital, Penang, Malaysia.

Daniel Gonzalez-Padilla (D)

Department of Urology, University Hospital 12 de Octubre, Madrid, Spain.

Daniele Castellani (D)

Department of Urology, IRCCS INRCA, Ancona, Italy.

Justin M Dubin (JM)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Francesco Esperto (F)

Department of Urology, Campus Biomedico University of Rome, Rome, Italy.

Riccardo Campi (R)

Department of Urology, Careggi Hospital, University of Florence, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Kalyan Gudaru (K)

Department of Urology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK.

Ruchika Talwar (R)

Division of Urology, University of Pennsylvania, Philadelphia, PA, USA; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.

Zhamshid Okhunov (Z)

Department of Urology, University of California, Irvine, Orange, CA, USA.

Chi-Fai Ng (CF)

S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.

Nitesh Jain (N)

Department of Urology, Apollo Main Hospital, Chennai, Tamil Nadu, India.

Vineet Gauhar (V)

Department of Urology, Ng Teng Fong General Hospital, NUHS, Singapore.

Martin Chi-Sang Wong (MC)

JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.

Marcelo Langer Wroclawski (ML)

Hospital Israelita Albert Einstein, Sao Paulo, Brazil; BP-a Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil.

Yiloren Tanidir (Y)

Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.

Juan Gomez Rivas (JG)

Department of Urology, La Paz University Hospital, Madrid, Spain; Young Academic Urologist-Urotechnology Working Party (ESUT-YAU), European Association of Urology, Arnhem, The Netherlands.

Ho-Yee Tiong (HY)

Department of Urology, National University Hospital, Singapore.

Stacy Loeb (S)

Department of Urology, New York University, New York, NY, USA; Department of Population Health, New York University, New York, NY, USA; Manhattan VA Medical Center, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH